Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study
Rattachement africain : ru, by. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment. Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS in real-world clinical practice. Material and methods. The results of TLT with Revelisa were analyzed in 1181 patients with IS: 616 (52.2%) women and 565 (47.8%) men (mean age 68.28±12.56 years), of which 140 (11.9%) with staged reperfusion. The mean time from disease onset to TLT was 2.58±0.83 hours. The Heidelberg classification was used to assess hemorrhages during neuroimaging. Symptomatic hemorrhagic transformation (HT) was defined according to ECASS III criteria. The study group was characterized by high comorbidity: arterial hypertension (96.9%), ischemic heart disease (56.7%), chronic heart failure (55.8%) and cardiac arrhythmias (33.3%) were most common; diabetes mellitus was present in 23% of patients. IS occurred repeatedly in 15.4% of cases. Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41% of patients. The dynamics of the decrease in neurological symptoms one day later and at the time of discharge were statistically significant (p<0.001). The hospital mortality rate for the entire group was 8%, for the TLT group without endovascular intervention 5.6%. Twenty-nine patients (2.46%) had symptomatic HT, 14 of whom underwent endovascular intervention. The proportion of patients with a favorable clinical outcome (0–2 points on the modified Rankin scale) at discharge and at day 90 was 50.1% and 65.5%, respectively. Conclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.><0.001). The hospital mortality rate for the entire group was 8%, for the TLT group without endovascular intervention 5.6%. Twenty-nine patients (2.46%) had symptomatic HT, 14 of whom underwent endovascular intervention. The proportion of patients with a favorable clinical outcome (0–2 points on the modified Rankin scale) at discharge and at day 90 was 50.1% and 65.5%, respectively. Conclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study
- Date Crossref
- 17/02/2025
- Éditeur
- IMA Press, LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Federal Center of Brain Research and Neurotechnologies pays non établi dans la noticeOrganisme public
-
Federal Medical-Biological Agency pays non établi dans la noticeOrganisme public
-
Kazan State Medical University Interregional Clinical and Diagnostic Center pays non établi dans la noticeUniversité ou école supérieure
-
Ministry of Health of the Russian Federation pays non établi dans la noticeOrganisme public
-
Republican Scientific and Practical Center of Neurology and Neurosurgery pays non établi dans la noticeStructure de recherche
-
City Clinical Hospital pays non établi dans la noticeÉtablissement de santé
-
Samara Regional Clinical Hospital named after V.D. Seredavina pays non établi dans la noticeÉtablissement de santé
-
Specialized Clinical Psychiatric Hospital No. 1 pays non établi dans la noticeÉtablissement de santé
-
Samara City N.I. Pirogov Clinical Hospital №1 pays non établi dans la noticeÉtablissement de santé
-
Regional Children's Clinical Hospital No. 1 pays non établi dans la noticeÉtablissement de santé
-
State Autonomous Institution of Health Interregional Clinical Diagnostic Center pays non établi dans la noticeÉtablissement de santé
-
St. Petersburg State Medical Academy "City Hospital No. 26" pays non établi dans la noticeÉtablissement de santé
Federal Center of Brain Research and Neurotechnologies, Federal Medical-Biological Agency et Interregional Clinical and Diagnostic Center — Kazan State Medical University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.